期刊
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH
卷 17, 期 2, 页码 109-119出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14737167.2017.1292852
关键词
Vildagliptin; cost-effectiveness; Brazil; type 2 diabetes; metformin
资金
- National Council for Scientific and Technological Development (CNPq)
- Foundation for Research Support of the State of Minas Gerais (FAPEMIG)
- Newton Advanced Fellowship by Academy of Medical Sciences, through the UK Government's Newton Fund program
- Academy of Medical Sciences (AMS) [AMS-NAF1-GuerraJunior] Funding Source: researchfish
Introduction: Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian context.Areas covered: Using MEDLINE, Cochrane Library, Lilacs and CRD, six studies were selected for the economic models. This study utilised cost data in the Brazilian health system to provide the context.Expert commentary: Type 2 diabetes mellitus is an epidemic disease and represents a challenge for all health care systems. Although guidelines clearly define first-line treatment, there are several other promising treatments. Vildagliptin is one of them, resulting in a mean lifetime increase of 0.31years compared to metformin alone and 1.19 more life years compared to other metformin combinations. Considering observational data, life years with dual vildagliptin-containing treatments were 0.37 more compared to other dual treatments. However, its high cost versus generic metformin and its unclear safety profile weakens its subsequent cost-effectiveness. Consequently, the incorporation of vildagliptin or its combination with metformin is currently not recommended for the Brazilian Health Care System. This may change as more data becomes available.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据